Alfonso Martínez de la Cruz
amartinez
Alfonso Martínez de la Cruz
ASSOCIATE PRINCIPAL INVESTIGATOR
Liver Disease Lab
Address: Bizkaia Science and Technology Park, building 801A, Derio (Bizkaia)

Luis Alfonso Martínez de la Cruz obtained his BSc in Chemistry from the Autonomous University of Madrid (UAM) and continued his scientific pursuits by completing his PhD in Chemistry at Autonomous University of Madrid and Instituto de Química Física Rocasolano, CSIC, Madrid.

In 1997, Dr. Martínez de la Cruz moved to Heidelberg, Germany, where he undertook his first postdoctoral stage focused on Proteins Crystallography in the laboratory headed by Wolfgang Kabsch and Kenneth Holmes at the Biophysics Department of the Max Planck Institute for Medical Research.  He later received a Postdoctoral Scholar position in the Sung-Hou Kim´s laboratory at the University of California at Berkeley, USA, funded by MEC/Fulbright and the Department of Chemistry, to conduct research in Biochemistry and Structural Biology. In 2000, Dr. Martínez de la Cruz returned to the University of Navarra, CIMA, as a Postdoctoral Researcher. By 2001, he had become an Associate Research Scientist.

In 2005, Dr. Martínez de la Cruz joined CIC bioGUNE, where he led the Structural Biology Unit until 2020. At that time, he became an Associate Principal Investigator in the Liver Disease Lab, headed by Dr. Malu Martínez-Chantar. His research continues to focus on the structural-functional relationships of enzymes involved in reverse transsulfuration, hydrogen sulfide production and cellular magnesium transport, and their implications in rare pathologies, cancer, and bacterial/fungal multidrug-resistant pathogen infections. Since 2019, he has been an associate professor at the School of Medicine of the University of Deusto, Bilbao.

Awards & recognitions
MEC Fullbright Postdoctoral Fellowship (1997-1999). NATO Postdoctoral Fellowship (1997).

Collaborations
ML Tremblay (Mc Gill, Montreal). D. Müller (Charité-Universitätsmedizin Berlin). J Hoenderop (Radboudumc, Netherlands). T Majtan (Univ. Fribourg). A. Astegno (Univ. Verona). D. Buccela, NYU, USA. DW. Al-Sadeq & Gheyath Nasrallah (Qatar University). Drita Siliqi (Univ. Bari, Italy). G. Jiménez-Osés, U. Marigorta and ML Martínez-Chantar (CIC bioGUNE). I Díaz Moreno (CSIC, Univ. Sevilla). I Quintana (IK4-TEKNIKER). A. Cabrera (HIPOFAM patients association).

Latest Publications

2023

2021

The Liver Disease Lab's research primarily focuses on understanding the molecular mechanisms underlying liver diseases, with a special emphasis on the role of methionine metabolism and post-translational modifications in liver function and pathology.

The general research objective is to elucidate the biochemical and genetic pathways that contribute to liver disorders such as non-alcoholic fatty liver disease (NAFLD), liver fibrosis, and hepatocellular carcinoma. By studying these mechanisms, the group aims to develop targeted therapies and diagnostic tools that can effectively prevent, manage, or treat these liver conditions. Their work integrates basic biochemical research with translational studies to bridge the gap between laboratory findings and clinical applications, ultimately improving patient outcomes in liver diseases.

The Liver Disease Lab has established four innovative research domains, including two previously unexplored areas. These advancements have markedly enhanced our understanding of liver metabolism, physiology, and disease.

Research line 1: Post-translational modifications
Particularly NEDDylation and SUMOylation, exploring how these modifications regulate metabolic pathways in liver disease, resulting in significant publications and the development of new therapeutic strategies.

Research line 2: Mitochondrial activity
Investigating the role of mitochondrial dysfunction in liver disease, which affects cell energy metabolism and has implications for conditions like NAFLD and liver cancer.

Research line 3: Glutamine metabolism
Focusing on how glutamine metabolism and ammonium production impact liver disease progression from NAFLD to hepatocellular carcinoma.

Research line 4: Metallomics
Studying the metabolism of elements like magnesium and ammonium, identifying their roles in liver function and disease, leading to innovative therapeutic approaches.
The laboratory has developed new biological tools, preclinical animal models, and therapeutic strategies, resulting in patented innovations and robust translational research aimed at clinical application.

Collaborations
Dr. Martinez-Chantar's lab collaborated with international companies, including JD Biosciences, SILENCE Therapeutics, and Alnylam Pharmaceuticals, on liver disorder treatments, and initiated partnerships with Tekniker and Gaiker for the development of low-cost point-of-care (POC) diagnostics, as well as with Histocell for cell therapy in liver disease. She boasts an extensive network of collaborators both nationally and internationally, see: https://pubmed.ncbi.nlm.nih.gov/?term=martinez-chantar&size=200

Latest Publications

The lipopolysaccharide-TLR4 axis regulates hepatic glutaminase 1 expression promoting liver ammonia build-up as steatotic liver disease progresses to steatohepatitis

Mercado-Gómez, M; Goikoetxea-Usandizaga, N; Kerbert, AJC; Gracianteparaluceta, LU; Serrano-Macía, M; Lachiondo-Ortega, S; Rodriguez-Agudo, R; Gil-Pitarch, C; Simón, J; González-Recio, I; Fondevila, ...

METABOLISM-CLINICAL AND EXPERIMENTAL

2024-09-01

Neddylation inhibition prevents acetaminophen-induced liver damage by enhancing the anabolic cardiolipin pathway.

Gil-Pitarch, Claudia; Serrano-Macia, Marina; Simon, Jorge; Mosca, Laura; Conter, Carolina; Rejano-Gordillo, Claudia M; Zapata-Pavas, L Estefania; Pena-Sanfelix, Patricia; Azkargorta, Mikel; ...

Cell reports. Medicine

2024-07-16

Phosphorylation at the disordered N-end makes HuR accumulate and dimerize in the cytoplasm

Baños-Jaime, B; Corrales-Guerrero, L; Pérez-Mejias, G; Rejano-Gordillo, CM; Velázquez-Campoy, A; Martínez-Cruz, LA; Martínez-Chantar, ML; de la Rosa, MA; Díaz-Moreno, I;

NUCLEIC ACIDS RESEARCH

2024-07-05

Mitochondrial antiviral signaling protein enhances MASLD progression via the ERK/TNFα/NFκβ pathway

Novoa, E; Lima, ND; Gonzalez-Rellan, MJ; Chantada-Vazquez, MDP; Verheij, J; Rodriguez, A; Esquinas-Roman, EM; Fondevila, MF; Koning, M; Fernandez, U; Cabaleiro, A; Parracho, T; Iglesias-Moure, ...

HEPATOLOGY

2024-05-16

Proceedings of the 5th Meeting of Translational Hepatology, organized by the Spanish Association for the Study of the Liver (AEEH).

Alvarado-Tapias, Edilmar; Maya-Miles, Douglas; Albillos, Agustin; Aller, Rocio; Ampuero, Javier; Andrade, Raul J; Arechederra, Maria; Aspichueta, Patricia; Banales, Jesus M; Blas-Garcia, Ana; ...

Gastroenterologia y hepatologia

2024-05-07

Targeting hepatic stellate cells to combat liver fibrosis: where do we stand?

Breitkopf-Heinlein, K; Martinez-Chantar, ML;

GUT

2024-04-24

Catalytic specificity and crystal structure of cystathionine γ-lyase from Pseudomonas aeruginosa

Pedretti, M; Fernandez-Rodriguez, C; Conter, C; Oyenarte, I; Favretto, F; di Matteo, A; Dominici, P; Petrosino, M; Martinez-Chantar, ML; Majtan, T; Astegno, A; Martinez-Cruz, LA;

SCIENTIFIC REPORTS

2024-04-23

Neddylation orchestrates the complex transcriptional and posttranscriptional program that drives Schwann cell myelination

Ayuso-García, P; Sánchez-Rueda, A; Velasco-Avilés, S; Tamayo-Caro, M; Ferrer-Pinós, A; Huarte-Sebastian, C; Alvarez, V; Riobello, C; Jiménez-Vega, S; Buendia, I; Cañas-Martin, J; Fernández-Susavila, ...

SCIENCE ADVANCES

2024-04-12

Biochemical and structural impact of two novel missense mutations in cystathionine β- synthase gene associated with homocystinuria

Al-Sadeq, DW; Conter, C; Thanassoulas, A; Al-Dewik, N; Safieh-Garabedian, B; Martínez-Cruz, LA; Nasrallah, GK; Astegno, A; Nomikos, M;

BIOCHEMICAL JOURNAL

2024-04-02

SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer

Lachiondo-Ortega, S; Rejano-Gordillo, CM; Simon, J; Lopitz-Otsoa, F; Delgado, TC; Mazan-Mamczarz, K; Goikoetxea-Usandizaga, N; Zapata-Pavas, LE; García-del Río, A; Guerra, P; Peña-Sanfélix, ...

CELL REPORTS

2024-03-26

Effect of Gracilaria vermiculophylla Macroalga on Non-Alcoholic Fatty Liver Disease in Obese Rats

González-Arceo, M; Aguirre, L; Macarulla, MT; Gil-Pitarch, C; Martínez-Chantar, ML; Portillo, MP; Gómez-Zorita, S;

ANTIOXIDANTS

2024-03-01

p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway

Fondevila, MF; Novoa, E; Gonzalez-Rellan, MJ; Fernandez, U; Heras, V; Porteiro, B; Parracho, T; Dorta, V; Riobello, C; Lima, ND; Seoane, S; Garcia-Vence, M; Chantada-Vazquez, MP; Bravo, SB; ...

CELL REPORTS MEDICINE

2024-02-20

Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

Rodríguez-Agudo, R; González-Recio, I; Serrano-Maciá, M; Bravo, M; Petrov, P; Blaya, D; Herranz, JM; Mercado-Gómez, M; Rejano-Gordillo, CM; Lachiondo-Ortega, S; Gil-Pitarch, C; Azkargorta, M; ...

JHEP REPORTS

2024-01-01

Mitochondrial dysfunction-associated microbiota establishes a transmissible refractory response to anti-TNF therapy during ulcerative colitis

Peña-Cearra, A; Castelo, J; Lavín, JL; Gonzalez-Lopez, M; Pascual-Itoiz, MA; Fuertes, M; de Juan, VG; Bárcena, L; Martín-Ruiz, I; Pellón, A; Seoane, I; Barriales, D; Palacios, A; Fullaondo, ...

GUT MICROBES

2023-12-18

Ratiometric Fluorescent Sensors Illuminate Cellular Magnesium Imbalance in a Model of Acetaminophen-Induced Liver Injury

Brady, M; Shchepetkina, VI; González-Recio, I; Martínez-Chantar, ML; Buccella, D;

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

2023-10-02

Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

Claveria-Cabello, A; Herranz, JM; Latasa, MU; Arechederra, M; Uriarte, I; Pineda-Lucena, A; Prosper, F; Berraondo, P; Alonso, C; Sangro, B; Marin, JJG; Martinez-Chantar, ML; Ciordia, S; Corrales, ...

JOURNAL OF HEPATOLOGY

2023-10-01

Neddylation of phosphoenolpyruvate carboxykinase 1 controls glucose metabolism

Gonzalez-Rellan, MJ; Fernández, U; Parracho, T; Novoa, E; Fondevila, MF; Lima, ND; Ramos, L; Rodríguez, A; Serrano-Maciá, M; Perez-Mejias, G; Chantada-Vazquez, P; Riobello, C; Veyrat-Durebex, ...

CELL METABOLISM

2023-09-05

The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

Goikoetxea-Usandizaga, N; Bravo, M; Egia-Mendikute, L; Abecia, L; Serrano-Maciá, M; Urdinguio, RG; Clos-García, M; Rodríguez-Agudo, R; Araujo-Legido, R; López-Bermudo, L; Delgado, TC; Lachiondo-Ortega, ...

HEPATOLOGY

2023-09-01

Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function

Gonzalez-Rellan, MJ; Parracho, T; Heras, V; Rodriguez, A; Fondevila, MF; Novoa, E; Lima, N; Varela-Rey, M; Senra, A; Chantada-Vazquez, MDP; Ameneiro, C; Bernardo, G; Fernandez-Ramos, D; Lopitz-Otsoa, ...

MOLECULAR METABOLISM

2023-09-01

Dissecting the role of the NADPH oxidase NOX4 in TGF-beta signaling in hepatocellular carcinoma

Espinosa-Sotelo, R; Fusté, NP; Peñuelas-Haro, I; Alay, A; Pons, G; Almodóvar, X; Albaladejo, J; Sánchez-Vera, I; Bonilla-Amadeo, R; Dituri, F; Serino, G; Ramos, E; Serrano, T; Calvo, M; Martínez-Chantar, ...

REDOX BIOLOGY

2023-09-01